Risk factor
Very poor trading liquidity
Profitability factor
Strong growth
About
Clover Corporation Limited engages in the processing and worldwide sale of natural oils, reaching markets across Australia, New Zealand, Asia, Europe, and the Americas. The company's operations also encompass the creation of encapsulated products and extensive research and development focused on functional food and infant nutrition ingredients. Among its principal offerings are Nu-Mega Hi docosahexaenoic tuna oils, designed for use in infant formula and pharmaceutical goods, alongside its Ocean Gold refined tuna oils. Furthermore, it supplies Nu-Mega Driphorm powders, which are incorporated into various infant formulas, follow-on formulas, growing-up milks, and general food products, as well as Nu-Mega Driphorm HA for non-dairy applications. These products cater to several segments, including active living (for immune and sports support), healthy living (benefiting brain and heart health), and the foundational stages of infant and child development. The company, founded in 1988, maintains its corporate headquarters in Altona North, Australia.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, r
Target Price
The average target price of CLV.AX is 0.87 and suggests 1.14% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to